Insider Purchases: Inside the Buy

Tag: Small Cap Stocks

Digital healthcare check-in kiosks in a modern clinic with a falling stock chart in the background and an investor buying during the dip, symbolizing Phreesia’s market selloff and insider confidence.

Phreesia (PHR): Profitable… Then Crushed — Why Insiders Are Loading Up

Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.

Read entire article

Tags: buy or sell PHR, featured-insiders, Fintech, fintech healthcare, FUNanc1al, FUNanc1al Investing, growth stocks, healthcare SaaS, healthcare tech, HealthcareSaaS, high growth stocks, hub-hedge, hub-insiders, insider buying, InsiderBuying, PHR, PHR stock, Phreesia, risks buying PHR, SaaS investing, small cap stocks, stock ideas, stock market analysis, StockMarket2026, turnaround stocks, undervalued stocks, value investing, ValueInvesting, why buy PHR
A futuristic U.S. titanium manufacturing facility with robotic arms assembling aerospace components, symbolizing advanced materials and reshoring.

IPX Stock: America’s Titanium Comeback—or a Costly Experiment? 🦾

IperionX is betting on a U.S. titanium comeback. With government backing and disruptive tech, the upside is huge—but so are the risks.

Read entire article

2 comments
|
Tags: Advanced Manufacturing, buy or sell IPX, Critical Minerals, CriticalMinerals, Defense Stocks, DefenseStocks, featured-insiders, FUNanc1al, FUNanc1al Investing, FUNanc1al Stocks, hub-insiders, Industrial Tech, Investing2026, IperionX, IPX, IPX Stock, Materials Sector, PennyStocks, Reshoring, risks buying IPX, Small Cap Stocks, Speculative Stocks, Titanium, Titanium Industry, why buy IPX
Illustration of an antibody molecule breaking through a descending stock chart, symbolizing AbCellera’s biotech turnaround and short squeeze potential.

AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?

Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.

Read entire article

Tags: AbCellera Biologics, ABCL, AndrewBoothCFO, Baker Bros, Biotech Stocks, BuyOrSellABCL, CFO Andrew Booth, Clinical Trials, featured-overseas, FUNanc1al Edge, FUNanc1al Investing, FunStock Index, High Risk Investing, hub-hedge, hub-insiders, hub-overseas, Insider Buying, John Montalbano, RisksBuyingABCL, Short Squeeze, Small Cap Stocks, WhyBuyABCL
Illustration of a stylized crown hovering above biotech molecules and financial charts, representing XOMA Royalty’s strategy of collecting biotech royalties without developing drugs.

Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!

XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.

Read entire article

Tags: Biotech Royalties, Biotech Stocks, buy-or-sell-XOMA, CEO buy, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, CEOConfidence, featured-insiders, funanc1al edge, funanc1al humor, FUNanc1al Investing, FUNstock Income + Growth, Healthcare Investing, hub-diversify, hub-epiphany, hub-fun, hub-hedge, hub-insiders, hub-ipos, hub-overseas, hub-ridiculous, hub-special-files, hub-value, Insider Buying, risks-investing-in-xoma, Royalty Stocks, Small-Cap Stocks, why-buy-xoma, XOMA, XOMA Royalty